Outlook Therapeutics, Inc.
OTLK
$1.37
-$0.02-1.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.39M | 28.25M | 20.68M | 20.58M | 20.58M |
| Gross Profit | -33.39M | -28.25M | -20.68M | -20.58M | -20.58M |
| SG&A Expenses | 36.09M | 29.94M | 27.10M | 25.78M | 26.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.99M | 71.70M | 61.28M | 59.86M | 47.76M |
| Operating Income | -82.99M | -71.70M | -61.28M | -59.86M | -47.76M |
| Income Before Tax | -46.81M | -75.36M | -94.05M | -159.13M | -51.50M |
| Income Tax Expenses | 2.80K | 2.80K | 2.80K | 2.80K | 2.80K |
| Earnings from Continuing Operations | -46.81 | -75.37 | -94.05 | -159.13 | -51.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.81M | -75.37M | -94.05M | -159.13M | -51.50M |
| EBIT | -82.99M | -71.70M | -61.28M | -59.86M | -47.76M |
| EBITDA | -82.87M | -71.59M | -61.19M | -59.78M | -47.70M |
| EPS Basic | -5.14 | -6.72 | -7.95 | -11.48 | -3.99 |
| Normalized Basic EPS | -3.00 | -3.97 | -4.71 | -6.57 | -2.26 |
| EPS Diluted | -7.94 | -9.51 | -10.75 | -11.48 | -3.99 |
| Normalized Diluted EPS | -3.08 | -4.05 | -4.80 | -6.57 | -2.26 |
| Average Basic Shares Outstanding | 85.46M | 74.24M | 63.51M | 53.13M | 51.69M |
| Average Diluted Shares Outstanding | 87.71M | 76.49M | 65.76M | 53.13M | 51.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |